Labcorp Holdings Inc. (LH) Cash Flow Statement

Operating cash flow exceeded net income by a wide margin in several quarters, most notably Q4 2024 and Q4 2025, which may indicate favorable working capital releases rather than structurally stronger earnings. The near-zero conversion in Q1 2025, when working capital absorbed $444.7M, suggests reported profits may not translate consistently into cash. Investors should monitor whether conversion normalizes toward a more stable range over the next several reporting periods.

The recent FCF margin of 10.8% in Q3 2026 sits below the 20.0% peak reached in Q4 2024, suggesting the business is not yet back to its earlier cash generation levels. Trailing free cash flow has been volatile, with the 2025 quarters showing large swings driven largely by working capital rather than steady operating improvement. Investors may want to assess whether the recent recovery reflects sustainable operating gains or temporary balance sheet timing.

Capex has remained in a fairly tight band across the ten quarters, which may indicate that spending is weighted toward maintaining existing laboratory infrastructure rather than large growth projects. Depreciation and amortization of roughly $170M to $183M per quarter exceeds capex in most periods, which could suggest the asset base is being maintained at a pace below its consumption rate. Investors should monitor whether underinvestment in automation erodes the labor-intensity advantages that support margins over time.

The magnitude of working capital swings relative to net income suggests collection timing, payables management, or contract-related accruals are materially influencing reported operating cash flow. Large reversals, such as the $329.7M release followed by heavy absorption in subsequent quarters, may point to timing effects rather than durable improvements. Given the provision for doubtful accounts and percentage-of-completion accounting in the Biopharma segment, investors should examine whether these balances are normalizing or accumulating.

Acquisition spending has been the largest use of cash in multiple quarters, consistent with the company's bolt-on M&A strategy in hospital lab outsourcing. Dividend payments remain stable and appear well covered in cash terms during stronger quarters, though weaker quarters such as Q1 2025 show limited cushion. Investors should evaluate whether acquired returns on invested capital justify the sustained cash outlay, particularly if organic growth remains in the mid-single digits.